Abstract

The cortex of *Machilus thunbergii,* which has been consumed as traditional herbal medicine for treatment of leg edema and abdominal distension and pain for a long period of time. In this study, the combination effect of *M. thunbergii* ethanol extract (MTEE) was evaluated against oral bacteria, either alone or with antibiotics, via broth dilution method and checkerboard and time kill assay. MIC/MBC values for MTEE against all the tested bacteria ranged between 12.5-50/50-200 microg/mL, for ampicillin 0.0625-8/0.125-32 microg/mL and for gentamicin 4-128/8-512 microg/mL respectively. Furthermore, the MIC and MBC were reduced to one half-eighth as a result of the combination of MTEE with antibiotics. 1-6 hours of treatment with 1/2 MIC of MTEE with 1/2 MIC of antibiotics resulted from an increase of the rate of killing in units of CFU/mL to a greater degree than was observed with alone. These results suggest that the MTEE is important in the antibacterial actions of oral pathogens agents.

**Abbreviations.** MTEE: *Machilus thunbergii* ethanol extract; MICs: Minimum inhibitory concentrations; MBCs: Minimum bactericidal concentrations; CFU: Colony Forming Unit; FIC index: Fractional Inhibitory Concentration; FBC index: Fractional Bactericidal Concentration index.

**Introduction**

Oral disease is one of the most important preventable infectious diseases, a major health problem in dental caries and periodontal disease [1,2]. Oral health affects the general quality of life and poor oral health is associated with chronic conditions and systemic diseases [3-5]. There are more than 750 bacteria in the oral cavity, many of which are related to oral diseases [6]. The development of dental caries includes acidogenic and aciduric gram-positive bacteria, mainly mutans streptococci (*Streptococcus mutans* and *S. sobrinus*), lactobacilli and actinomycetes, which metabolize sucrose into organic acids that dissolve the calcium phosphate in teeth, causing decalcification and eventual decay [6-8]. In contrast, periodontal disease is subgingival and gum diseases associated with anaerobic gram-negative bacteria such as *Porphyromonas gingivalis*, Actinobacillus sp., Prevotella sp., and *Fusobacterium* sp. [9-11]. In periodontal disease, gingival crevices or areas beneath the gingiva are infected, causing cellular inflammatory response of the gingiva and surrounding connective tissue [10,11]. These inflammatory reactions can be caused by gingivitis (extremely common and seen as bleeding of the gingival or gum tissues) or periodontitis (the inflammatory response results in loss of collagen attachment of the tooth to the bone and in loss of bone) [12-14].

Many plant-derived medicines used in traditional medicinal systems have been documented in pharmacopoeias for the treatment of infections and a number of these have been recently proved effective against oral microbial pathogens [15-18]. *Machilus thunbergii* (Laureaceae) is widely distributed in Korea. The cortex of *M. thunbergii,* which has been consumed as traditional herbal medicine for treatment of leg edema and abdominal distension and pain for a long period of time [19-21]. Isoquinoline alkaloids have been obtained from the root, lignin, catechin and polysaccharides from the heartwood, polysaccharides, and essential oils from the leaves, volatile components from the fruits, and lignins and neolignans from the cortex [22-24]. Some of these compounds are antioxidants with hepatoprotective, and anti-bacterial activities, while a few other show inhibitory effects on nitric oxide synthesis inactivated macrophages and neuroprotective activity against glutamate-induced neurotoxicity [22,25, 26]. Machilin A (MA), one of the lignans shows biological activities, including stimulation of osteoblast differentiation via activation of p38 mitogen-activated protein (MAP) kinases in an *in vitro* osteoblasts [20].

In this study, we investigated the synergistic antibacterial activity of *M. thunbergii* ethanol extract (MTEE) in combination with existing antimicrobial agents against oral bacteria.

**Key words:** *machilus thunbergii,* antibacterial activity, oral pathogen bacteria, synergistic effect, minimum inhibitory concentrations (MICs), minimum bactericidal concentrations (MBCs)

**Received:** November 06, 2018; **Accepted:** November 22, 2018; **Published:** November 27, 2018

**Correspondence to:** Jeong-Dan Cha, Research Manager, Material Development Team, R&D Center, General Bio Co., Ltd., 254 Yongtusna-ro, Songdong-myeon, Namwon-si, Jeollabuk-do, 55793 Republic of Korea, Tel. +82-63-263-0001, Fax: +82-70-5101-1563, E-mail: cjd@generalbio.co.kr

*Eun-Jin Jang 1, Sung-Mi Choi 2 and Jeong-Dan Cha* *&*

1 Department of Dental Technology, Daegu Health College, Daegu, Republic of Korea
2 Department of Dental Hygiene, Daegu Health College, Daegu, Republic of Korea
3 Material Development Team, R&D Center, General Bio Co., Ltd. Namwon-si, Republic of Korea
Materials and methods

Bacterial strains

The oral bacterial strains used in this study were: Streptococcus mutans ATCC 25175, Streptococcus sanguinis ATCC 10556, Streptococcus sobrinus ATCC 27607, Streptococcus rattii KCTC (Korean collection for type cultures) 3294, Streptococcus criceti KCTC 3292, Streptococcus anginosus ATCC 31412, Streptococcus gordonii ATCC 10558, Aggregatibacter actinomycetemcomitans ATCC 43717, Fusobacterium nucleatum ATCC 10953, Prevotella intermedia ATCC 25611, and Porphyromonas gingivalis ATCC 33277. Brain–Heart Infusion (Difco Laboratories, Detroit, MI) broth supplemented with 1% yeast extract (Difco) was used for all bacterial strains except *P. intermedia* and *P. gingivalis*. For *P. intermedia* and *P. gingivalis*, BHI broth containing hemin 1 μg/mL (Sigma, St. Louis, MO, USA) and menadione 1 μg/mL (Sigma) was used.

Minimum inhibitory concentrations/minimum bactericidal concentrations assay

The minimum inhibitory concentrations (MICs) were determined for *M. thunbergii* ethanol extract (MTEE) by the broth dilution method, and were carried out in triplicate (27). The antibacterial activities were examined after incubation at 37°C for 18 h (facultative anaerobic bacteria), for 24 h (microaerophilic bacteria), and for 1-2 days (obligate anaerobic bacteria) under anaerobic conditions. MICs were determined as the lowest concentration of test samples that resulted in a complete inhibition of visible growth in the broth. MIC<sub>s</sub> and MIC<sub>c</sub>s, defined as MICs at which, 50 and 90%, respectively of oral bacteria were inhibited, were determined. Following anaerobic incubation of MICs plates, the minimum bactericidal concentrations (MBCs) were determined on the basis of the lowest concentration of MTEE that kills 99.9% of the test bacteria by plating out onto each appropriate agar plate. Ampicillin (Sigma) and gentamicin (Sigma) were used as standard antibiotics in order to compare the sensitivity of MTEE against oral bacteria.

Checker-board dilution test

The antibacterial effects of a combination of MTEE, which exhibited the highest antimicrobial activity, and antibiotics were assessed by the checkerboard test as previously described (27). The antimicrobial combinations assayed included MTEE with ampicillin or gentamicin. Serial dilutions of two different antimicrobial agents were mixed in cation-supplemented Mueller–Hinton broth. After 24-48 h of incubation at 37°C, the MICs were determined to be the minimal concentration at which there was no visible growth and MBCs were determined on the basis of the lowest concentration of MTEE that kills 99.9% of the test bacteria by plating out onto each appropriate agar plate. The fractional inhibitory concentration (FIC)/ fractional bactericidal concentration (FBC) index was calculated according to the equation: FIC/FBC index= FIC/FBC<sub>A</sub> + FIC/FBC<sub>B</sub> = (MIC/MBC of drug A in combination/ MIC/MBC of drug A alone) + (MIC/MBC of drug B in combination/ MIC/MBC of drug B alone). The FIC and FBC index are the sum of the FICs and FBCs of each of the drugs, which in turn is defined as the MIC and MBC of each drug when it is used in combination divided by the MIC and MBC of the drug when it is used alone. The interaction was defined as synergistic if the FIC and FBC index was less than or equal to 0.5, additive if the FIC and FBC index was greater than 0.5 and less than or equal 1.0, indifferent if the FIC and FBC index was greater than 1.0 and less than or equal to 2.0, and antagonistic if the FIC and FBC index was greater than 2.0 (27).

Time-kill curves

Bactericidal activities of the drugs under study were also evaluated using time-kill curves on oral bacteria. Tubes containing Mueller–Hinton supplemented to which antibiotics had been added at concentrations of the MIC<sub>c</sub>s were inoculated with a suspension of the test strain, giving a final bacterial count between 5–6.6×10<sup>6</sup> CFU/ml. The tubes were thereafter incubated at 37°C in an anaerobic chamber and viable counts were performed at 0, 0.5, 1, 2, 3, 4, 5, 6, 12 and 24 h after addition of antimicrobial agents, on agar plates incubated for up to 48 h in anaerobic chamber at 37°C. Antibiotic carryover was minimized by washings by centrifugation and serial 10-fold dilution in sterile phosphate-buffered saline, pH 7.3. Colony counts were performed in duplicate, and means were taken. The solid media used for colony counts were BHI agar for streptococci and BHI agar containing hemin and menadione for *P. intermedia* and *P. gingivalis*.

Results and discussion

Minimum inhibitory concentrations/minimum bactericidal concentrations of MTEE and antibiotics

MTEE evaluated the antimicrobial activities against eleven bacterial species present in the oral cavity.

The results of the antimicrobial activity showed that MTEE exhibited antimicrobial activities against cariogenic bacteria (MICs, 12.5 to 50 μg/mL; MBCs, 50 to 200 μg/mL) against periodontopathogenic bacteria (MICs, 25 to 50 μg/mL; MBCs, 50 to 200 μg/mL) and ampicillin showed a concentration of 0.0625/8–0.125/32 μg/mL, while gentamicin showed a concentrations of 4/8–128/512 μg/mL on tested all bacteria (Table 1). The range of MIC<sub>c</sub>s and MIC<sub>bc</sub>s were from 3.13 to 12.5 μg/mL and 12.5 to 50 μg/mL, respectively. The MTEE showed stronger antimicrobial activity against *S. gordonii* (MIC/MBC, 12.5/50 μg/mL) than another bacteria (MIC/MBC, 25/50–50/200 μg/mL) and the range of MIC<sub>c</sub>s and MIC<sub>bc</sub>s were 3.13 μg/mL and 12.5 μg/mL.

Synergistic effect of MTEE with antibiotics

Natural products are a major source of chemical diversity and have provided important treatment agents for many bacterial diseases [16,27-29]. The combination of some natural products and antibiotics can increase the antimicrobial activity of antibiotics [30,31]. The synergistic effects of MTEE alone or with antibiotics were evaluated in oral bacteria (Tables 2 and 3). In combination with MTEE, the MIC for ampicillin was reduced ≥4-fold in all tested bacteria, producing a synergistic effect as defined by FICI ≤ 0.5, except *S. gordonii* by FICI<sub>0.75</sub> and additive. The MBC for ampicillin was shown synergistic effects in all tested bacteria by FBCI ≤ 0.5, except *S. ratti*, *S. criceti*, and *P. gingivalis* by FICI<sub>0.75</sub> and additive (Table 2). In combination with MTEE, the MIC for gentamicin was reduced ≥4-8-fold in all tested bacteria, except *S. criceti* and *P. gingivalis* by FICI ≥ 0.75 and MBC in all tested bacteria by FBCI ≤ 0.5, except *S. sanguinis*, *S. ratti*, *S. anginosus*, and *F. nucleatum* by FBCI ≤ 0.75 (Table 3).

Phytochemical constituents such as alkaloids, flavonoids, tannins, phenols, saponins, and several other aromatic compounds are secondary metabolites of plants that serve a defence mechanism against prediction by many microorganisms, insects and other herbivores [32-35]. Flavonoid complexes attach with extra cellular soluble protein and with bacterial cell wall [36,37]. Lignans, alkaloids, flavonoids, butanolides, and essential oils have been derived from *M. thunbergii*; some of these compounds are antioxidants with hepatoprotective and antibacterial activities [23,25,26]. Both the ethyl acetate fraction and water fraction
Table 1. Antibacterial activity of the Machilus thunbergii ethanol extract (MTEE) and antibiotics in oral bacteria

| Samples          | Agent (MIC/MBC (μg/mL)) | MTEE (μg/mL) | Ampicillin (μg/mL) | Gentamicin (μg/mL) |
|------------------|-------------------------|--------------|-------------------|-------------------|
|                  | MIC<sub>50</sub> | MIC<sub>90</sub> | MIC<sub>MBC</sub> | MIC<sub>MBC</sub> | FIC/FBC | FIC/FBC | Outcome                   |
| S. mutans        | ATCC 25175          | 6.25         | 25                | 25/100            | 0.125/0.25 | 8/16 |
| S. sanguinis     | ATCC 10556          | 12.5         | 50                | 50/200            | 0.0625/0.125 | 16/32 |
| S. sobrinus      | ATCC 27607          | 6.25         | 25                | 25/50             | 0.25/0.5   | 8/32 |
| S. ratti         | KCTC 3294          | 12.5         | 50                | 50/100            | 0.25/0.5   | 8/16 |
| S. criceti       | KCTC 3292          | 6.25         | 25                | 25/100            | 0.0625/0.125 | 8/16 |
| S. anginosus     | ATCC 31412          | 12.5         | 50                | 50/200            | 0.125/0.25 | 8/16 |
| S. gordonii      | ATCC 10558          | 3.13         | 12.5              | 12.5/50           | 0.125/0.5  | 16/32 |
| A. actinomycetemcomitans | ATCC 43717 | MTEE 25 | 50                | 25/100            | 8/32   | 8/16 |
| F. nucleatum    | ATCC 51190         | 6.25         | 25                | 25/100            | 8/16   | 4/8    |
| P. intermedia   | ATCC 49049         | 12.5         | 50                | 50/100            | 1/2     | 32/64  |
| P. gingivalis   | ATCC 33277         | 6.25         | 25                | 25/100            | 0.5/1   | 128/512 |

<sup>1</sup>The MIC and MBC of the Machilus thunbergii ethanol extract (MTEE) with ampicillin
<sup>2</sup>The fractional inhibitory concentration (MIC) index/fractional bactericidal concentration (MBC) index
<sup>3</sup>American Type Culture Collection (ATCC)
<sup>4</sup>Korean collection for type cultures (KCTC)

Table 2. Synergistic effects of Machilus thunbergii ethanol extract (MTEE) with ampicillin against oral bacteria

| Strains | Agent (MIC/MBC (μg/mL)) | MTEE (μg/mL) | Ampicillin (μg/mL) | Gentamicin (μg/mL) |
|---------|-------------------------|--------------|-------------------|-------------------|
|         | MIC<sub>50</sub> | MIC<sub>90</sub> | MIC<sub>MBC</sub> | MIC<sub>MBC</sub> | FIC/FBC | FIC/FBC | Outcome                   |
| S. mutans | ATCC 25175          | 6.25         | 25                | 25/100            | 0.25/0.25 | 0.5/0.375 | Synergistic/  Synergistic |
| S. sanguinis | ATCC 10556        | 12.5         | 50                | 50/200            | 0.25/0.5   | 0.5/0.375 | Synergistic/ Synergistic |
| S. sobrinus | ATCC 27607        | 6.25         | 25                | 25/50             | 0.25/0.5   | 0.5/0.5  | Synergistic/ Synergistic |
|         |                     |              |                   |                   | 0.5/0.75  | 0.5/0.5  | Synergistic/  Synergistic |
| S. ratti  | ATCC 3294          | 12.5         | 50                | 50/100            | 0.25/0.25 | 0.5/0.75  | Synergistic/  Synergistic |
| S. criceti | ATCC 3292         | 6.25         | 25                | 25/100            | 0.5/0.25  | 0.5/0.75  | Synergistic/  Synergistic |
| S. anginosus | ATCC 31412       | 3.13         | 12.5              | 12.5/50           | 0.125/0.25 | 0.75/0.5 | Additive/  Synergistic |
| S. gordonii | ATCC 10558        | 6.25         | 25                | 25/100            | 0.5/1     | 0.5/0.5  | Synergistic/  Synergistic |
| A. actinomycetemcomitans | ATCC 43717 | Ampicillin 8/32 | 2/8               | 0.25/0.25        |
| F. nucleatum | ATCC 51190        | 6.25         | 25                | 25/100            | 0.25/0.25 | 0.5/0.375 | Synergistic/ Synergistic |
| P. intermedia | ATCC 49049       | 12.5         | 50                | 50/100            | 0.5/0.5   | 0.5/0.5  | Synergistic/  Synergistic |
| P. gingivalis | ATCC 33277       | 6.25         | 25                | 25/100            | 0.5/0.5   | 0.5/0.5  | Synergistic/  Synergistic |

<sup>1</sup>The MIC and MBC of the Machilus thunbergii ethanol extract (MTEE) with ampicillin
<sup>2</sup>The fractional inhibitory concentration (MIC) index/fractional bactericidal concentration (MBC) index
<sup>3</sup>American Type Culture Collection (ATCC)
<sup>4</sup>Korean collection for type cultures (KCTC)

of Machilus thunbergii bark and leaf show antimicrobial activity against all the tested Gram-positive bacteria, *Staphylococcus aureus* were 0.1 mg/mL and 0.5 mg/mL [38]. In this study, *M. thunbergii* ethanol extract shows susceptibility on gram-positive bacteria as well as gram-negative bacteria [38].

**Time kill of MTEE with antibiotics**

The bacterial effect of MTEE with ampicillin or gentamicin against oral bacteria was confirmed by time-kill curve experiments. The MTEE (MIC or MBC) alone resulted rate of killing increasing or not
changing in CFU/mL at time dependent manner, with a more rapid rate of killing by MTEE (MIC$_{50}$) with ampicillin (MIC$_{50}$) or gentamicin (MIC$_{50}$) (Figures 1-3). A strong bactericidal effect was exerted in drug combinations.

In conclusion, these findings suggest that MTEE fulfills the conditions required of a novel cariogenic bacteria and periodontal pathogens, particularly bacteroides species drug and may be useful in the future in the treatment of oral bacteria.

Table 3. Synergistic effects of *Machilus thunbergii* ethanol extract (MTEE) with gentamicin against oral bacteria

| Strains             | Agent          | MIC/MBC (μg/ml) | FIC/FBC | FICI/FIBCI$^3$ | Outcome          |
|---------------------|----------------|-----------------|---------|----------------|-----------------|
|                     |                | Alone | Combination$^1$ |        |                |                 |
| *S. mutans* ATCC 25175$^3$ | MTEE          | 25/100 | 6.25/25            | 0.25/0.25 | 0.5/0.5         | Synergistic/ Synergistic |
|                     | Gentamicin     | 8/16 | 2/4                | 0.25/0.25 |                 |                  |
| *S. sanguinis* ATCC 10556 | MTEE          | 50/200 | 12.5/50             | 0.25/0.25 | 0.5/0.75         | Synergistic/ Additive |
|                     | Gentamicin     | 16/32 | 4/16               | 0.25/0.5  |                 |                  |
| *S. sobrinus* ATCC 27607 | MTEE          | 25/50  | 6.25/12.5           | 0.25/0.25 | 0.5/0.5          | Synergistic/ Synergistic |
|                     | Gentamicin     | 16/32 | 4/8                | 0.25/0.25 |                 |                  |
| *S. ratti* KCTC 3294$^3$ | MTEE          | 50/100 | 12.5/50             | 0.25/0.5  | 0.5/0.75         | Synergistic/ Additive |
|                     | Gentamicin     | 8/32  | 2/8                | 0.25/0.25 |                 |                  |
| *S. criceti* KCTC 3292 | MTEE          | 25/100 | 12.5/25             | 0.5/0.25  | 0.75/0.5         | Additive/ Synergistic |
|                     | Gentamicin     | 8/16  | 2/4                | 0.25/0.25 |                 |                  |
| *S. anginosus* ATCC 31412 | MTEE          | 50/200 | 12.5/50             | 0.25/0.25 | 0.5/0.75         | Synergistic/ Additive |
|                     | Gentamicin     | 8/16  | 2/8                | 0.25/0.5  |                 |                  |
| *S. gordonii* ATCC 10558 | MTEE          | 12.5/50 | 3.13/12.5           | 0.25/0.25 | 0.5/0.5          | Synergistic/ Synergistic |
|                     | Gentamicin     | 16/32 | 4/8                | 0.25/0.25 |                 |                  |
| *A. actinomycetemcomitans* ATCC 43717 | MTEE          | 50/200 | 12.5/25              | 0.25/0.125 | 0.5/0.375        | Synergistic/ Synergistic |
|                     | Gentamicin     | 8/16  | 2/8                | 0.25/0.5  |                 |                  |
| *F. nucleatum* ATCC 51190 | MTEE          | 25/100 | 6.25/25              | 0.25/0.25 | 0.5/0.75         | Synergistic/ Additive |
|                     | Gentamicin     | 4/8   | 1/4                | 0.25/0.5  |                 |                  |
| *P. intermedia* ATCC 25611 | MTEE          | 50/100 | 12.5/25              | 0.25/0.25 | 0.5/0.375        | Synergistic/ Synergistic |
|                     | Gentamicin     | 32/64 | 8/8                | 0.25/0.125 |                 |                  |
| *P. gingivalis* ATCC 33277 | MTEE          | 25/50  | 12.5/12.5           | 0.5/0.25  | 0.75/0.375       | Additive/ Synergistic |
|                     | Gentamicin     | 128/512 | 32/64               | 0.25/0.125 |                 |                  |

$^1$The MIC and MBC of the *Machilus thunbergii* ethanol extract (MTEE) with gentamicin

$^2$The fractional inhibitory concentration (FIC) index/fractional bactericidal concentration (FBC) index

$^3$American Type Culture Collection (ATCC)

$^4$Korean collection for type cultures (KCTC)

Figure 1. Time-kill curves of MICs of the *Machilus thunbergii* ethanol extract (MTEE) alone and in combination with MICs of ampicillin or gentamicin against *S. mutans*, *S. sanguinis*, *S. sobrinus*, and *S. ratti*. Bacteria were incubated with METK along (●), METK with ampicillin (○), and METK with gentamicin (▲) over time. Data are presented as the mean ± SD of the four experiments. CFU, colony-forming units
Figure 2. Time-kill curves of MICs of the *Machilus thunbergii* ethanol extract (MTEE) alone and in combination with MICs of ampicillin or gentamicin against *S. criceti*, *S. anginosus*, *S. gordonii*, and *A. actinomycetemcomitans*. Bacteria were incubated with MTEE along (●), MTEE with ampicillin (○), and MTEE with gentamicin (▲) over time. Data are presented as the mean ± SD of the four experiments. CFU, colony-forming units.

Figure 3. Time-kill curves of MICs of the *Machilus thunbergii* ethanol extract (MTEE) alone and its combination with MICs of ampicillin or gentamicin against *F. nucleatum*, *P. intermedia*, and *P. gingivalis*. Bacteria were incubated with MTEE along (●), MTEE with ampicillin (○), and MTEE with gentamicin (▲) over time. Data are presented as the mean ± SD of the four experiments. CFU, colony-forming units.
Declaration of interest
The authors declare no conflict of interest.

Sources of funding
This study was not funded by any organization.

Ethical approval
This study has no need for prior approval by an ethics committee.

References
1. Costalonga M, Herzberg MC (2014) The oral microbiome and the immunobiology of periodontal disease and caries. *Immuno Lett* 162: 22-38. [Crossref]
2. Stroussi HY, Epstein JB, Bensadoun RJ, Saunders DP, et al. (2017) Common oral complications of head and neck cancer radiation therapy: mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease, and osteoradionecrosis. *Cancer Med* 6: 2918-2931. [Crossref]
3. Chi AC, Neville BW, Krzyz JY, Gonsalves WA (2010) Oral manifestations of systemic disease. *Am Fam Physician* 82: 1381-1388. [Crossref]
4. Kumar PS (2017) From focal sepsis to periodontal medicine: a century of exploring the role of the oral microbiome in systemic disease. *J Physiol* 595: 465-476. [Crossref]
5. Sampaio-Maia B, Caldas JM, Pereira ML, Pérez-Mongiovì D, Araujo R (2016) The Oral microbiome in health and its implication in oral and systemic diseases. *Adv Appl Microbiol* 97: 171-210. [Crossref]
6. Arweiler NB, Netuschil I (2016) The oral microbiota. *Adv Exp Med Biol* 902: 45-60. [Crossref]
7. Mickenauchtsch S, Leal SC, Yengopul V, Bezerra AC, Cruvinel V (2007) Sugar-free chewing gum and dental caries: a systematic review. *J Appl Oral Sci* 15: 83-88. [Crossref]
8. Morou-Bermudez E, Loza-Herrero MA, Garcia-Rivas V, Suarez-Perez E, Billings RJ (2017) Oral bacterial acid-base metabolism in caries screening: A proof-of-concept study. *JDM Clin Trans Res* 2: 132-141. [Crossref]
9. Ardila CM, López MA, Guzmán IC (2011) Positive correlations between presence of gram negative enteric rods and Porphyromonas gingivalis in subgingival plaque. *Acta odontoligica Latinoamericana* 24: 15-19.
10. Oliveira RR, Ferniano D, Ferres M, Figueiredo LC, Teles FR, et al. (2016) Levels of candidate periodontal pathogens in subgingival biofilm. *J Dent Res* 95: 711-718.
11. Pinto G, Silva MD, Peddley M, Sillankorva S, Arazedo J (2016) The role of bacteriophages in periodontal health and disease. *Future Microbiol* 11: 1359-1369. [Crossref]
12. Wu YH, Kuraji R, Taya Y, Ito H, et al. (2018) Effects of rheatinus on tissue inflammation and bone resorption on experimental periodontitis in rats. *J Periodontal Res* 53: 1009-1019. [Crossref]
13. Kinane DF, Stathopoulos PG, Papapanou PN (2017) Periodontal diseases. *Nat Rev Dis Primers* 3: 17038. [Crossref]
14. Hienz SA, Paliwal S, Ivanovski S (2015) Mechanisms of bone resorption in periodontitis. *J Immunol* 2015: 615486. [Crossref]
15. Kokoska L, Kloucek P, Leuner O, Nový P (2018) Plant-derived products as antibacterial and antifungal agents in human health care. *Curr Med Chem*. [Crossref]
16. Nakagami H, Tomomura M (2018) Dental application of natural products. *Medicines* (Basel) 5. [Crossref]
17. Nabavi SM, Marchese A, Izadi M, Curti V, Daglia M, et al. (2015) Plants belonging to the genus Thymus as antibacterial agents: from farm to pharmacy. *Food Chem* 173: 339-347. [Crossref]
18. Santosh RS, Saruyanarayanan B (2014) Plants: a source for new antimycobacterial drugs. *Planta Med* 80: 9-21. [Crossref]
19. Ma CJ, Kim YC, Sung SH (2009) Compounds with neuroprotective activity from the medicinal plant Machilus thunbergii. *J Enzyme Inhib Med Chem* 24: 1117-1121.
20. Lee MK, Yang H, Ma CJ, Kim YC (2007) Stimulatory activity of lignans from Machilus thunbergii on osteoblast differentiation. *Bioll Pharm Bull* 30: 814-817.
21. Kim SJ, You J, Choi HG, Kim JA, Jee YG, et al. (2015) Selective inhibitory effects of maclin A isolated from Machilus thunbergii on human cytochrome P450 1A1 and 2B6. *Pharmaceutical* 22: 615-620.
22. Li L, Shi H, Zhang S, Hu T, Wang J, et al. (2018) First report of lassiodiplodia gilannensis causing twig and leaf blight on machilus thunbergii in zhejiang province of China. *Plant Dis.*
23. Su YC, Hsu KP, Li SC, Ho CL (2015) Composition, in vitro cytotoxicity, and anti-mildew activities of the leaf essential oil of machilus thunbergii from Taiwan. *Nat Prod Commun* 10: 2013-2016. [Crossref]
24. Pan LY, Chen WN, Chiu ST, Raman A, Chiang TC, et al. (2015) Is a gall an extended phenotype of the inducing insect? A comparative study of selected morphological and physiological traits of leaf and stem galls on Machilus thunbergii (Lauraceae) induced by five species of duphaphila (Diptera: Cecidomyidae) in northeastern Taiwan. *Zoolog Sci* 32: 314-321.
25. Yu YU, Kang SY, Park HY, Sung SH, Lee EJ, et al. (2000) Antioxidant lignans from Machilus thunbergii protect CC14-injured primary cultures of rat hepatocytes. *J Pharm Pharmacol* 52: 1163-1169.
26. Kim NY, Ryu JH (2003) Butanolides from Machilus thunbergii and their inhibitory activity on nitric oxide synthesis in activated macrophages. *Phytother Res* 17: 372-375.
27. Chu JD, Jeong MR, Jeong SI, Lee KY (2007) Antibacterial activity of sophorafavanone G isolated from the roots of Sophora flavescens. *J Microbiol Biotechnol* 17: 856-864.
28. Vieweg L, Reichau S, Schobert R, Leadlay PF, Süssmuth RD (2014) Recent advances in the field of bioactive tetrates. *Nat Prod Rep* 31: 1554-1584. [Crossref]
29. Diefenbach AL1, Muniz FWMG1, Oballe HJR1, Rösing CK1 (2018) Antimicrobial activity of copaiba oil (Copaifera sop.) on oral pathogens: Systematic review. *Phytother Res* 32: 586-596. [Crossref]
30. Hema'iswarya S, Kruhiveti AK, Deble M (2008) Synergism between natural products and antibiotics against infectious diseases. *Phytotherapy* 15: 639-652.
31. Ma XY, Zheng CJ, Han LY, Xie B, Jia J, et al. (2009) Synergistic therapeutic actions of herbal ingredients and their mechanisms from molecular interaction and network perspectives. *Drug Discov Today* 14: 579-588.
32. Politeo O, Skocibasic M, Carev I, Burcul F, Jerkovic I, et al. (2012) Phytochemical profiles of volatile constituents from Centaurea ragusina leaves and flowers and their antimicrobial effects. *Nat Prod Commun* 7: 1087-1090.
33. Wright B, Spencer JP, Lovegrove JA, Gibbs JM (2013) Insights into dietary flavonoids as molecular templates for the design of anti-platelet drugs. *Cardiovasc Res* 97: 13-22. [Crossref]
34. Mishra BB, Tiwari VK (2011) Natural products: an evolving role in future drug discovery. *Eur J Med Chem* 46: 4769-4807. [Crossref]
35. Yamamoto H, Ogawa T (2002) Antimicrobial activity of perilla seed polyphenols against oral pathogenic bacteria. *Biosci Microbio Biochem* 66: 921-924.
36. Yusouk K, Weeranantanaporn O, Hua Y, Kumkrai P, Chudapongse N (2017) Lupinifolin from Derris reticulata possesses bactericidal activity on Staphylococcus aureus by disrupting bacterial cell membrane. *J Nat Med* 71: 357-366. [Crossref]
37. La VD, Labrecque J, Grenier D (2009) Cytotoxic preemptive effect of protoanemonidin-rich cranberry fraction against bacterial cell wall-mediated toxicity in macrophages and epithelial cells. *Phytother Res* 23: 1449-1452.
38. See KS, Yun KW (2018) Comparative evaluation of antimicrobial and antioxidant potential of bark and leaf of magnolia obvata THUNB. and Machilus thunbergii S. et Z. *J Pharm Sci* 10: 528-531.

Copyright: ©2018 Jang E. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.